China gives glimpse of Fujian aircraft carrier's catapult technology in action
most advanced aircraft carrier, the Fujian
Advertisement
CCTV included the footage of the
electromagnetic catapult system in a report last week, with a view from an unidentified aircraft hurtling along the deck.
But the report also dampened speculation that the Fujian would be ready for service this year, pointing out that the complexity of the launch system meant that it would need
longer sea trials than China's other carriers, the Liaoning and Shandong.
The short footage was accompanied by vision of an air traffic control officer on the bridge of the Fujian giving take-off clearance to an aircraft on 'position one' of the carrier's launch system. The report did not specify where or when the manoeuvres were filmed.
According to the CCTV report, the Fujian's crew have done a 'complete reform' in take-off and landing training to master the catapult system – the world's second after the USS Gerald Ford-class aircraft carriers.
Advertisement
The report quoted commentator Cao Weidong, who said the adoption of the electromagnetic catapult system meant that the Fujian's carrier-based aircraft would take off with full fuel and full ordnance.
'Fixed-wing early warning aircraft may board the ship soon. It may also test small aircraft such as drones,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
6 minutes ago
- South China Morning Post
China reveals past EV subsidies, from Tesla to state giants – where did the money go?
China has released a breakdown of the subsidy settlements for new-energy vehicle (NEV) companies from 2016 to 2020, along with the allocation plan for 2021 to 2022, and the data helps illustrate how the industry landscape shifted during those years. According to data released by the Ministry of Industry and Information Technology (MIIT) earlier this month, over the seven years from 2016 to 2022, subsidies gradually moved from traditional state-owned enterprises to leading carmakers and emerging start-ups. A total of 1.65 billion yuan (US$230 million) in subsidies was disbursed between 2016 and 2020. The Beijing Electric Vehicle Co. emerged as the biggest winner, receiving about 556 million yuan, or a third of the total. Meanwhile, BYD received only 15.74 million yuan, and Tesla, which first applied for subsidies in 2020, received 3.59 million yuan – each sum accounted for less than 1 per cent of the total. The MIIT explained that several carmakers received less than their requested amounts due to non-compliant documentation or failure to upload required vehicle data. The subsidy plans for 2023-2024 have yet to be publicised. From 2021 to 2022, a clear shift in subsidy distribution began to emerge. BYD's Shaanxi and Shenzhen subsidiaries were allocated 37.91 million yuan and 35.56 million yuan, respectively, while Tesla's Shanghai subsidiary received 30.15 million yuan. Stellantis-backed electric vehicle (EV) maker Leapmotor was the only start-up to receive subsidies, totalling 2.76 million yuan. The data shows how subsidies increasingly favoured leading carmakers and select new entrants, signalling a transition from state-owned dominance to a more diversified market, said Zhou Lijun, director and chief researcher of auto industry analysis firm Yiche Research. Authorities will dynamically adjust NEV subsidy policies, with subsidies expected to gradually decrease, according to Zhou.
South China Morning Post
6 minutes ago
- South China Morning Post
China Telecom subsidiary says AI wave drives steady growth in digital services market
China Communication Services, the country's leading telecommunications infrastructure contractor, said a wave of artificial intelligence projects is now driving digital transformation in thousands of industries and providing a boost to the company's three major business segments. Beijing -based China Comservice, a subsidiary of China Telecom , made that assessment on Thursday as the firm reported its latest financial results, which showed growth in both revenue and net profit in the first six months of the year. The Hong Kong -listed company reported a 3.4 per cent year-on-year increase in revenue to 76.94 billion yuan (US$10.71 billion), while net profit rose a modest 0.2 per cent to 2.13 billion yuan. 'AI has a significant effect in driving the development of the company's various businesses,' said Luan Xiaowei, executive director and chairman at China Comservice. Shares of China Comservice closed up 2.10 per cent to HK$4.86 on Thursday. The applications, content and other services business segment remains the core driver of revenue growth for China Comservice. Photo: Handout The company's latest interim results reflect how it continued to benefit from AI application projects and heightened demand for digital transformation across thousands of industries on the mainland, it said.
South China Morning Post
3 hours ago
- South China Morning Post
China vows stronger biotech support as deals with global pharmaceutical giants surge
Chinese Premier Li Qiang has called for stronger policy support for the biotech industry, as part of efforts to bolster innovation in a sector that has witnessed a boom in recent years. 'The biopharmaceutical industry is both a strategic emerging sector and vital to public health,' he said during an inspection in Beijing on Wednesday, as reported by the state-run Xinhua News Agency. 'Efforts should be made to strengthen original innovation, address core technological challenges and mobilise resources from the government and market to achieve breakthroughs quickly.' Li also urged research institutes to focus on global frontiers and critical areas, while training top talent to establish a solid foundation for the sector's development. His remarks came as Chinese biotech developers continue to sign increasing numbers of out-licensing agreements with multinational pharmaceutical companies. Out-licensing involves biotech firms selling drug candidates, which have often completed Phase I and II trials in China, to global partners. Chinese drug developers have widely adopted the model to ease financial pressures in an industry where embracing new therapeutic approaches has proven cash-intensive and carries a high risk of failure. With China's healthcare system largely government-funded, steep price cuts under its national insurance scheme also limit domestic profitability.
